Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction

View Full Paper
Ask AI
Bookmark
Share

Authors

BJBrian JohnstoneJJJie JiangDGDong-sheng Gu

Discussion

Loading...

Member takes

Overview

Observational analysis shows enhanced GvHD prophylaxis in alloHCT with MSCs and extracellular vesicles, indicating potential for improved T cell regulation.

Key Points

  • Treatment with γSMCs improved T cell activation suppression in vitro, enhancing regulatory T cell induction.
  • In GvHD mouse models, γSMCs showed a 20% survival benefit at 28 days compared to controls.
  • Assessment involved Kaplan-Meier survival curves and dose-response relationships of EVs in T cell modulation.
  • Developing γSMCs suggests a promising avenue for next-generation GvHD prophylaxis interventions.

Cite This Study

Johnstone et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddf2https://doi.org/10.1182/blood-2025-4246
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy2025 · 3 citations
  2. 2Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis2025
  3. 3Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials2025 · 1 citations
  4. 4CDCP1+ mesenchymal stem cells preferentially inhibit acute graft-versus-host disease(aGVHD)2025
  5. 5Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial2025